Montelukast Ratiopharm (Montelukast)

Montelukast works as a selective antagonist of the cysteinyl leukotriene receptor CysLT1. Blocking this receptor stops leukotrienes D4, E4 and related molecules from causing bronchoconstriction, mucus production, vascular leakage and inflammatory cell recruitment, which together contribute to asthma and allergic rhinitis symptoms.

The appropriate dose of Montelukast Ratiopharm is determined by the prescribing healthcare professional based on the patient’s age, condition and response to therapy. Dosage regimens may differ for asthma, allergic rhinitis or exercise‑induced bronchoconstriction, and should always follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting β2‑agonists. While it is effective for certain patients, especially those with allergic components, it may be less potent than inhaled steroids for severe asthma. It can be used as add‑on therapy or when inhaler use is problematic.

Montelukast Ratiopharm tablets should be stored at room temperature, below 25 °C, in the original blister or container. Protect them from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Montelukast is taken orally, usually as a single tablet swallowed whole with or without food. The exact timing (e.g., in the evening) may be advised by the prescriber, and the tablet should not be chewed, crushed or split unless specifically instructed.

Serious risks include severe allergic reactions such as rash, angioedema or anaphylaxis, neuropsychiatric events like depression, anxiety or suicidal thoughts, and rare hepatic injury or severe skin disorders such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these symptoms appear.

Montelukast should be avoided in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it is not recommended as a sole therapy for acute asthma attacks. Clinical judgment is required for each patient.